AstraZeneca’s BioVentureHub has established a new collaboration with medtech company Mölnlycke to support knowledge exchange across the Swedish life science industry.

Small and medium-sized enterprises (SMEs) connected to AstraZeneca’s BioVentureHub will be offered free consultations with Mölnlycke experts with regard to developing products and solutions featuring medical device components.

“With increasing focus on precision medicine, patient centricity and preventative care, we need to think differently when we are designing healthcare solutions for the future. It’s not efficient nor sustainable to develop drugs, devices, diagnostics and digital health solutions in silos. As a life science industry, we need to build new structures for cross-sector collaboration and convergence . Our exciting collaboration with Mölnlycke further expands our unique collaboration environment, and offers SMEs and research groups invaluable access to Mölnlycke’s medtech expertise and know-how,” says Magnus Björsne, CEO, AstraZeneca BioVenturehub.

Daring to share

The collaboration, which has no financial, legal or contractual obligations, aims to support knowledge exchange across the Swedish life science industry, strengthen innovation opportunities for future, integrated, drug-device therapies and stimulate growth of SMEs. The collaboration with Mölnlycke follows a similar collaboration between the BioVentureHub and IBM Sweden announced earlier this year.

“We already have an R&D lab located in the BioVentureHub, and we’ve seen first-hand the important role the BioVentureHub is playing to facilitate interactions and unlock knowledge exchange to fuel the growth of the Swedish life science ecosystem. By daring to share more of the learnings and capabilities we have acquired over the years, we are pleased and proud to have the opportunity to contribute to further strengthen the development of the life science industry and help SMEs on the path to transformative growth in healthcare,” says Barry McBride, Executive Vice President, R&D at Mölnlycke.

Photo of Scientists collaborating – Gothenburg, Sweden: AstraZeneca